Ian Callaghan

Ian advises corporates, investment banks and alternative credit providers on public and private acquisition financings, cross-border syndicated lending, margin lending, fund financing arrangements and other structured financings.

Ian spent eight months on secondment to BNP Paribas’ loan syndication and trading team from 2009 to 2010 and eight months on secondment to Alcentra from 2013 to 2014, assisting their Collateralised Loan Obligation (CLO), direct lending and special situations teams.

Work highlights

Ian’s recent transactions include advising:

• Takeda Pharmaceutical Company on the $31bn financing for its £46bn recommended offer for Shire plc, the largest ever acquisition financing for a Japanese borrower  

• HSBC as global co-ordinator of the US$20bn offshore facilities to ChemChina for its c. $44bn public takeover offer for Syngenta AG (projected to be the largest outbound Chinese acquisition to date)
• a syndicate of international banks on a €321m margin loan secured over shares in a Greek listed company
• the lenders on the unitranche financing for OpenGate’s leveraged buy-out of Umicore Zinc Chemicals.
• a major corporate on a £510m facility for the issuance of demand guarantees to be used as collateral for its pension fund
• Kier Group plc on its syndicated facilities and other financing arrangements in connection with its acquisition of the Mouchel group
• Gold Fields Limited on its US$1.29bn revolving credit facilities
• Glencore plc on its $8bn revolving credit facilities

Ian provides pro bono advice on social housing issues at the regular drop-in centres run by the Mary Ward Centre.

Ian studied law at Clare College, Cambridge University.